Okapi Consult, in short

The purpose of Okapi Consult is to support companies in the biopharmaceutical and biotechnology sectors in corporate business development: the search for and establishment of strategic partnerships, technology transfers, in- and out-licensing agreements, and acquisitions, mergers and disposals of products, sites and entities.

Four marks, four things brought to a deal

A network on all continents, with deals closed in Japan, China, Korea, India, Turkey, Russia, Saudi Arabia, Egypt, Brazil, Canada, the United States and Germany. The ability to lead teams that share neither a language, a discipline nor a time zone, which is where most transactions are won or lost. Terms and conditions written with intent, the clauses that determine what a deal is worth long after the handshake. And an economist’s numbers reviewed by the same person who reviews the pharmacist’s science, so the assumptions in one are tested against the reality of the other.

How missions arrive

Client missions are found through the Walloon ecosystem and through a European and international network, the same networks that then identify partners for those clients.

In figures

Founded in July 2022, first client work in October 2022, seven clients in four years. Priority is given to start-ups and scale-ups, which benefit most from these services.